Moreover, only 2 tumors demonstrated mutations, which, as is the case in colorectal adenocarcinoma, has been suggested to confer resistance to anti-EGFR antibody therapy in ASCC [14]. Here, EGFR is linked to colorectal adenocarcinoma.